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Adalimumab, a subcutaneously administered human anti-TNF- monoclonal antibody, has recently been approved
by the FDA for the treatment of Crohn’s disease (CD). The
CHARM Trial was a multicenter clinical trial of the efficacy
and safety of adalimumab for the maintenance of disease
remission in moderate to severe CD.
Colombel et al reported the results of this randomized,
double-blind, placebo-controlled study conducted at 92 sites
in the US, Canada, Europe, Australia, and South Africa.
Enrolled patients had moderate to severely active CD
(Crohn’s disease activity index [CDAI] 220–450) and in-
cluded patients on stable doses of and azathioprine (AZA),
6-mercaptopurine (6-MP), methotrexate (MTX), 5-aminosal-
icylic acid (5-ASA), sulfasalazine, prednisone, or budes-
onide. Patients who had taken infliximab in the past were
included if: 1) their last dose was more than 12 weeks prior
and 2) they had an initial good response to infliximab. No-
table exclusion criteria included patients with an ostomy or a
history of recent or extensive small bowel resection.
All enrolled patients received adalimumab 80 mg sub-
cutaneously at week 0 followed by adalimumab 40 mg sub-
cutaneously at week 2. At week 4, patients were assessed for
response (decrease CDAI 70 from baseline) to adalimumab
induction. Subjects were then randomized to placebo, adali-
mumab 40 mg every other week (qow), or adalimumab 40 mg
weekly (qw) with treatment lasting through week 56. The
co-primary outcomes were the percent of week 4-randomized
responders who were in clinical remission (defined as CDAI
150) at 1) week 26 and 2) week 56. Several secondary
outcomes were explored and these included corticosteroid-
free remission rates and fistula closure rates.
Of 854 patients enrolled, 76 withdrew prior to random-
ization, 499 (58%) responded to induction and were random-
ized with 170 assigned to placebo, 172 assigned to adali-
mumab qow, and 157 assigned to adalimumab qw. Of the
randomized responders, 12%, 36%, and 41% of patients
assigned to placebo, qow adalimumab, and qw adalimumab,
respectively, were in clinical remission at week 56. The
differences between each adalimumab arm and the placebo
arm were statistically significant, but the differences between
the adalimumab schedules were not significant.
The secondary endpoint of corticosteroid-free remis-
sion was reported for randomized responders initially on
steroids. At week 56, 6%, 29%, and 23% of subjects taking
placebo, qow adalimumab, and weekly adalimumab, respec-
tively, had achieved steroid-free remission. Adalimumab was
also reported to be superior to placebo for fistula closure. Of
the subjects with fistulae, 30% of the pooled patients taking
adalimumab compared with 13% taking placebo demon-
strated fistula closure at week 26 with continued response at
week 56.
The most commonly reported adverse event was CD
exacerbation. This occurred at a significantly higher rate in
the placebo arm (32.2%) than among adalimumab-treated
patients (19.6% for every other week and 18.7% for every
week). Injection site reactions, urinary tract infection (UTI),
fatigue and headache occurred more commonly in 1 or both
of the adalimumab groups as compared with placebo. Serious
infectious adverse events were noted to be uncommon and
not significantly different between treatment and placebo
groups (2.7% and 3.4%, respectively). However, 2 cases of
tuberculosis were identified, both in patients treated with
adalimumab with negative purified protein derivatives
(PPDs) and chest x-rays at study entry.
COMMENT
The CHARM trial was a randomized, double-blind,
placebo-controlled study with concealed allocation in which
an intention-to-treat analysis was conducted, and all enrolled
patients were accounted for (those lost to follow-up, those
who withdrew from the study, those who switched to open-
label therapy, and those who did not have CDAI assessments
at weeks 26 and 56 were all considered failures to maintain
remission).
One omission in the presentation of the results is that
the reader is left to assume that randomization to the 3 arms
truly did produce unbiased groups. The authors report the
pooled baseline characteristics of the patients who were ran-
domized, but do not present the baseline characteristics of the
subjects in each of the 3 treatment arms. While bias is
relatively unlikely to occur in the randomization of 499
subjects to 3 arms, it is possible that unanticipated baseline
differences (i.e., in prior anti-TNF- use) could have an
impact on the results. This is highlighted by the primary
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efficacy analysis, which is adjusted for different rates of
previous anti-TNF- therapy in different study arms, al-
though the reader is not informed of what those rates were.
The primary aim of this trial was to determine the
maintenance rate of remission in patients treated with adali-
mumab who had a good initial response to induction therapy
and received continued maintenance dosing. The pooled
week 56 remission rate among initial responders treated with
adalimumab was 38.6%, compared with 11.7% for placebo.
This difference yields a pooled number needed to treat (NNT)
of 4 initial responder patients who would need to be main-
tained with adalimumab to achieve 1 extra week 56 remission
compared to placebo (exact NNT 3.71, 95% confidence in-
terval [CI] 2.93–5.06).
The patient population studied in this trial had a motley
treatment history. While nearly 50% had previously used a
TNF- antagonist, only 47% were on any immunosuppres-
sive agent (including AZA, 6-MP, and MTX), 39% were on
5-ASAs, and 44% were on corticosteroids. This shows that
real-world practice is far from standardized in either a step-up
or a top-down algorithm, and it suggests that adalimumab
may be efficacious for a wide range of patients.
One might expect that subjects with delayed infliximab
failure might be unresponsive to adalimumab, but both TNF-
antagonist-naı̈ve and TNF-antagonist-experienced patients on
adalimumab had significantly greater maintenance of remis-
sion versus placebo. The TNF-antagonist-naı̈ve patients did
have higher rates of remission versus those with delayed
infliximab failure (45% versus 32% in the pooled adali-
mumab-treated patients), and this difference was statistically
significant (benefit ratio 1.39, 95% CI 1.05–1.84, P  0.02).
Clinicians will have success with adalimumab in patients who
have had delayed infliximab failure, but they should expect to
have somewhat greater success rates in infliximab-naı̈ve pa-
tients.
How does adalimumab maintenance compare to other
immune modulators used for Crohn’s disease? It is impossi-
ble to make definitive comparisons between therapies evalu-
ated in different studies (due to differences in study patient
characteristics, study design, and the timing and definition of
the endpoints), but these results are not very different from
those reported for infliximab in ACCENT I, which had a
week 30 maintenance of remission NNT of 5.1 Similarly, the
NNT for MTX from Feagan et al.’s study of maintenance of
remission2 was 4 (exact NNT 3.83, 95% CI 2.09–22.81), and
the Cochrane Review of thiopurine maintenance for CD
calculates a NNT of 7.3 These are rather similar results for 4
immune system-modifying agents in CD. Each of these med-
ications has its own risks, including serious infection and
cancer, and these have to be carefully weighed by physicians
and patients. These medications also differ substantially in
cost, with 56-week medication costs from Drugstore.com4 of
US$260 for methotrexate, US$557 for azathioprine,
US$19,107 for adalimumab, and US$16,438 for infliximab
before infusion costs. Physicians and patients have to judge
the balance between risks, benefits, and costs when choosing
between these 4 medications. The large cost differential and
similar maintenance efficacy suggest that we should consider
MTX and AZA before using biologics.
The real-world effectiveness of adalimumab for main-
tenance is hard to estimate from a controlled clinical trial, but
patients and clinicians want a reasonable estimate of the
likelihood of success before they start a therapy, to help them
weigh the benefits against the risks and costs. For every 100
subjects started on adalimumab in this study (pooling the
results from both adalimumab schedules), 9 dropped out
before 4 weeks, and 33 had a poor response at 4 weeks. Of the
remaining 58 patients with a good week 4 response who
continued in the maintenance phase, only 22 were in remis-
sion at week 56, compared to 7 with placebo. This is clearly
superior to placebo, but the overall rate of remission at 1 year
is relatively low. This illustrates how far we still have to go
in the treatment of CD. Given the cost of adalimumab,
methods to prospectively identify the 22 patients out of 100
most likely to achieve sustained remission (perhaps via im-
munogenetic profiling) would be very helpful for future clin-
ical decision-making. Adalimumab appears to be a reason-
ably effective, reasonably well-tolerated, and quite expensive
treatment option for CD. Adalimumab is an important addi-
tion to our limited armamentarium against CD, and gives us
a good option when infliximab fails. Having infliximab as our
only biologic option in CD is reminiscent of the words of
Nigel Tufnel (referring to guitar amplifiers that only go up to
10 in This Is Spinal Tap): “Where can you go from there?
Nowhere.” Adalimumab now gives us another anti-TNF-
option.
Dahlia Awais, MD





1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab
for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:
1541–1549.
2. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate
with placebo for the maintenance of remission in Crohn’s disease. North
American Crohn’s Study Group Investigators. N Engl J Med. 2000;342:
1627–1632.
3. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercap-
topurine for maintenance of remission in ulcerative colitis. Cochrane
Database Syst Rev 2007:CD000478.
4. www.drugstore.com. Prescription Price Checker. Accessed April 24,
2007.
Inflamm Bowel Dis ● Volume 13, Number 10, October 2007 Should we be CHARMed
1309
